Gene Silencing/Gene Editing
News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.
Epigenetic Editing Firm Chroma Medicine Launches With $125M in Seed, Series A Financing
The Cambridge, Massachusetts-based startup plans to further develop its epigenetic editing platform and advance its pipeline of targeted therapeutics.
Israeli Government Extends CRISPR-IL Consortium With $14.5M in New Funding
The second 18-month phase of the program to develop AI technologies for gene editing seeks to validate and refine software developed since last year.
Single-Cell Genomics Study Elucidates Viral, Host Factors of Human Cytomegalovirus
The researchers use pooled CRISPR interference to define the function of each factor involved in the infection of primary human fibroblasts.
Inscripta Licenses MAD7 CRISPR Nuclease to Hunterian Medicine
Hunterian, based in Cambridge, Massachusetts, said it plans to use MAD7 in its gene editing programs to develop human therapeutics.
Synthego Preemptively Sues Agilent Technologies to Ward Off CRISPR Patent Infringement Allegations
Agilent allegedly tried to get Synthego to license patents related to CRISPR guide RNAs and threatened to escalate its response when Synthego did not do so.